A Meta-Analysis to Evaluate the Risk for Fatigue in Patients Treated with Olaparib for Advanced Cancer

Conference Correspondent —October 22, 2018


ESMO 2018

Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that is approved in the United States for patients with advanced breast cancer and advanced ovarian cancer. For patients receiving treatment for advanced cancer, fatigue and neuropathy―the latter in particular for those receiving platinum and/or taxanes―are among the most commonly reported adverse events.1 In this study, Ruiz-Schutz and colleagues performed a systematic literature review and meta-analysis of randomized controlled trials to characterize the risk for fatigue and neuropathy associated with the use of olaparib.

Nine studies representing 2074 patients with advanced ovarian, gastric, prostate, lung, or breast cancer were included in this analysis, with 908 (43.7%) patients receiving placebo/control treatments and 1166 (56.2%) receiving olaparib alone or in association with other active cancer treatments. Olaparib use was associated with increases in both all-grade fatigue (relative risk [RR], 1.24; 95% confidence interval [CI], 1.10-1.39) and high fatigue (hazard ratio [HR], 1.55; 95% CI, 1.14-2.09), as well as increases in high-grade fatigue (HR, 1.71; 95% CI, 1.06-2.77).

These results suggest that olaparib treatment is associated with an increased risk of fatigue. Given that fatigue is a very common treatment-related adverse event that can impair patients’ quality of life, it is important to identify it early and manage it accordingly to optimize overall treatment.


  1. Ruiz-Schutz, et al. ESMO 2018. Abstract 982P.
Related Articles
Initial Results from an Expansion Cohort Receiving Mirvetuximab Soravtansine/Pembrolizumab for Platinum-Resistant Ovarian Cancer: Initial Results from FORWARD II
Conference Correspondent
The antibody-drug conjugate mirvetuximab soravtansine combined with pembrolizumab has a manageable safety profile and encouraging signals of clinical activity.
Oregovomab and Nivolumab as a Combinatorial Immunotherapy Strategy for Recurrent Epithelial Ovarian Cance
Conference Correspondent
Based on the tolerable safety profile established in phase 1b of the ORION-01 trial, the recommended dose for expansion/recommended phase 2 dose of the oregovomab/nivolumab combination immunotherapy has been established.
Long-Term Tolerability of Olaparib Tablets as Maintenance Therapy for Platinum-Sensitive Relapsed Ovarian Cancer
Conference Correspondent
Similar to the capsule formulation, olaparib tablets have no cumulative toxicity, few late-onset adverse events, and a low rate of treatment discontinuation.
Last modified: October 22, 2018

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
  • Please enter your mailing address.

    Address Line 2
    Zip Code